Improving facial scars: comparing two fat grafting techniques using a nanofat graft

Submission date	Recruitment status No longer recruiting	Prospectively registered		
14/04/2024		[] Protocol		
Registration date	Overall study status	[] Statistical analysis plan		
22/04/2024	Completed	[] Results		
Last Edited	Condition category	Individual participant data		
22/04/2024	Skin and Connective Tissue Diseases	[_] Record updated in last year		

Plain English summary of protocol

Background and study aims

Despite the variety of therapeutic techniques used to improve the appearance of disfiguring scars, there is still no method that achieves perfect results, and nanofat injections have shown clinical benefits in rejuvenating the skin and improving the appearance of scars. Additionally, the concurrent use of platelet-rich fibrin with nanofat has shown an enhanced effect.

Who can participate? Patients aged 18 years old and over with atrophic linear facial scars

What does the study involve?

This study compares two groups of patients with atrophic facial scars. A control group will receive nanofat grafting and in contrast, the experimental group will receive unfiltered nanofat grafting with platelet-rich fibrin.

What are the possible benefits and risks of participating?

One of the features of nanofat grafting is the regeneration and improvement of the scar's texture and color in terms of pigmentation, restoring its thickness to the normal proportion of the surrounding skin. It is a safe, easy, and effective method due to its high content of adiposederived stem cells. However, this method has several limitations, including the presence of a donor surgical site and consequent complications such as pain, swelling, and infection.

Where is the study run from? Oral and Maxillofacial Surgery Hospital, Faculty of Dentistry, Damascus University, Syria

When is the study starting and how long is it expected to run for? January 2021 to January 2024

Who is the funding of the study? Investigator initiated and funded

Who is the main contact? Dr Mhd Anas Alnemr, anas.alnmer@gmail.com

Contact information

Type(s) Public, Scientific, Principal Investigator

Contact name Dr Mhd Anas Alnemr

ORCID ID https://orcid.org/0009-0002-9047-3030

Contact details Mezzeh Highway Damascus Syria 0000 +963957432950 anas1.alnmer@damascusuniversity.edu.sy

Type(s)

Public

Contact name Dr Mhd Anas Alnemr

Contact details

Mezzeh Highway Damascus Syria 0000 +963957432950 anas.alnmer@gmail.com

Additional identifiers

EudraCT/CTIS number Nil known

IRAS number

ClinicalTrials.gov number Nil known

Secondary identifying numbers Nil known

Study information

Scientific Title

The management of facial scars by using unfiltered nanofat graft mixed with platelet-rich fibrin or conventional nanofat graft

Study objectives

The use of nanofat mixed with platelet-rich fibrin is effective in the management of atrophic facial scars compared to conventional nanofat.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 21/03/2021, Ethics Scientific Committee at Damascus University (Oral and Maxillofacial Surgery Department - Faculty of Dental Medicine - Damascus University, Damascus, 4671, Syria; +963 11 33923011; verification.dicr@damascusuniversity.edu.sy), ref: DN-210224-11-H8

Study design

Single-blind randomized controlled clinical trial

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s) Medical and other records, University/medical school/dental school

Study type(s) Treatment, Efficacy

Participant information sheet

See study outputs table

Health condition(s) or problem(s) studied

Improving the appearance of atrophic facial scars in patients

Interventions

This study is a randomized controlled trial, including 2 groups of patients with atrophic facial scars - the control group will receive nanofat grafting. In contrast, the experimental group will receive unfiltered nanofat grafting with platelet-rich fibrin (PRF). Participants will be randomized into 2 groups using https://www.randomizer.org/.

The follow-up for each patient is 6 months with 3 visits for each patient:

- 1. One week postoperative
- 2.3 months postoperative
- 3.6 months postoperative

The primary outcome of the study is assessed using the Patient And Observer Scar Assessment Scale (POSAS) in 2 parts, firstly by 3 observers and secondly by the patient himself/herself. The observers will assess scar quality (vascularity, pigmentation, thickness, relief, pliability and

surface area) on a scale from 1 to 10. While the patient will assess according to the following parameters from 1 to 10: pain, itchiness, color, stiffness, thickness and irregularity.

Intervention Type

Procedure/Surgery

Primary outcome measure

Scar quality from the perspectives of the patient and the clinician measured using the Patient And Observer Scar Assessment Scale (POSAS) at baseline (T0: preoperative), 3 (T1) and 6 (T2) months postoperative

Secondary outcome measures

The following secondary outcome measures will be assessed at baseline (T0: preoperative), 3 (T1) and 6 (T2) months postoperative:

1. Scar appearance measured in 4 grades (Level 1: Macular Scar; Level 2: Mild Scar; Level 3: Moderate Scar; and, Level 4: Severe Scar) by 3 observers using the Goodman and Baron Scale 2. Aesthetic improvement measured using the Global Aesthetic Improvement Scale (7 levels: -3 = Very Much Worse; -2 = Much Worse; -1 = Worse; 0 = No Change; 1 = Improved; 2 = Much Improved; and, 3 = Very Much Improved)

Overall study start date

19/01/2021

Completion date

20/01/2024

Eligibility

Key inclusion criteria

- 1. Patients with atrophic linear facial scars
- 2. The length of the scar is more than 2 centimeters
- 3. Patients older than 18 years old
- 4. No systemic disease and syndromes
- 5. Previously untreated scars

Participant type(s)

Patient

Age group

Adult

Lower age limit

21 Years

Upper age limit 47 Years

Sex

Both

Target number of participants

20

Total final enrolment

24

Key exclusion criteria

- 1. Patients with acute skin disease
- 2. Patients with bleeding disorder
- 3. Patients has gone through severe weight gain/loss during the past few months
- 4. Skinny patients (does not have enough fat tissue in the donor sites)

Date of first enrolment 01/03/2022

Date of final enrolment 01/03/2023

Locations

Countries of recruitment Syria

Study participating centre Oral and Maxillofacial Surgery Hospital, Faculty of Dentistry, Damascus University Mazzeh Highway Damascus Syria 4671

Sponsor information

Organisation Damascus University

Sponsor details

Mazzeh Highway Damascus Syria 4671 +963944812030 vice.research@damascusuniversity.edu.sy

Sponsor type

University/education

Website

https://www.damascusuniversity.edu.sy/

ROR https://ror.org/03m098d13

Funder(s)

Funder type Other

Funder Name Investigator initiated and funded

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal

Intention to publish date 24/04/2024

. .

Individual participant data (IPD) sharing plan

The data sharing plans for the current study are unknown and will be made available at a later date

IPD sharing plan summary Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet			22/04/2024	No	Yes